Why Do People (Still) Go Blind from Glaucoma?
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Glaucoma is a progressive optic neuropathy and is the leading cause of irreversible blindness worldwide. Over 60 million people were estimated to be affected with open-angle glaucoma (OAG) in 2010, and bilateral blindness from the disease was estimated to be present in 4.5 million people with OAG in 2010, rising to 5.9 million people in 2020.1 In 1982, Grant and Burke2 published an article with a title similar to the present article suggesting three potential reasons why people go blind from glaucoma: one-third were undiagnosed; one-third had not been treated properly; and one-third were noncompliant with therapy. They also noted that, when abnormalities ranging from early glaucomatous cupping to advanced visual field defects were present at initial evaluation, progressive visual field loss continued to occur even with lowered intraocular pressure (IOP). In the consensus of Medical Treatment of Glaucoma by the World Glaucoma Association, the definition of target IOP includes the need to adjust therapy based on numerous factors, among them the initial level of damage, rate of progression, and life expectancy.3 It appears that eyes with more severe damage at presentation require lower IOP to prevent further functional loss or blindness. Forchheimer et al.4 investigated the relationship between baseline visual field damage, IOP, and rate of progression and found that among eyes with more severe functional damage (mean deviation [MD] worse than −12 dB), those with mean follow-up IOP < 14 mmHg progressed more slowly than those with higher pressures. Kotecha et al.5 found that following trabeculectomy, eyes showing changes in both optic nerve and visual field sensitivity had less IOP reduction from baseline compared with eyes showing no progression. Lee et al.6 reported that patients with more severe glaucomatous damage, as measured by both visual field and optic disc cupping, are at highest risk for rapid worsening of the disease and that more aggressive treatment of such patients should be considered to prevent visual disability. Heijl et al.7 showed that treatment is more effective in patients with MD better than −4.5 dB compared to patients with MD worse than −4.5 dB. Thirty years later, despite meaningful improvements in technology, therapeutic tools, and knowledge of the disease, patients continue to go blind from glaucoma. In a retrospective chart review by Peters et al.8 in Sweden, at the time of the last visit 42.2% and 16.4% of patients had at least one eye blind or bilateral blindness from glaucoma, respectively. Overall, the cumulative incidences of blindness in at least one eye and bilateral blindness from glaucoma were 26.5% and 5.5%, respectively, after 10 years, and 38.1% and 13.5% at 20 years.8 A recent report of the population-based study of all residents of Olmsted County, Minnesota,9 showed that the 20-year probability and the population incidence of blindness due to OAG in at least one eye decreased over the 45 years from 1965 to 2009. They also suggested that “… a subset of patients with glaucoma may have more aggressive disease and may be particularly susceptible to progression, possibly because of non-IOP-related factors that contribute to retinal ganglion cell (RGC) death and vision loss.”4 Although there is compelling evidence that “non-IOP-related factors” may indeed have a significant role in glaucoma pathogenesis,10–12 IOP is the major component associated with fast progression rate.13 In a recent review on the pathophysiology of glaucoma, Weinreb et al.14 stated that although the loss of ganglion cells is related to the level of IOP, other factors may also play a role. To date, there is no high-level evidence that non-IOP lowering medications can alter the progression of glaucoma. Yet, it is possible that other treatments may be needed to supplement IOP lowering or to make a given amount of IOP lowering more effective. Our working hypothesis is that even after 30 years of substantial advances in the field, the challenges faced by patients and eye care providers to prevent blindness due to glaucoma have not changed as substantially.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
The number of people with glaucoma worldwide in 2010 and 2020
Quigley, H. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.081224 · Cited by 7,394
The Pathophysiology and Treatment of Glaucoma: A Review
Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014) · JAMA · doi:10.1001/jama.2014.3192 · Cited by 4,210 · cited 2×
“In a recent review on the pathophysiology of glaucoma, Weinreb et al.(14) stated that although the loss of ganglion cells is related to the level of IOP, other factors may also play a role.”
InfluentialKirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Heijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,320
Number of people with glaucoma worldwide.
Quigley, H. A. (1996) · British Journal of Ophthalmology · doi:10.1136/bjo.80.5.389 · Cited by 2,998 · cited 2×
“Remo Susanna Jr.(1), Carlos Gustavo De Moraes(2), George A.”
(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Gordon, M. O. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.714 · Cited by 2,626
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Factors for Glaucoma Progression and the Effect of Treatment: The Early Manifest Glaucoma Trial
Leske, M. C. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.48 · Cited by 2,030
Sommer, A. (1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080080050026 · Cited by 1,178
Quigley, H. A. (1982) · Archives of Ophthalmology · doi:10.1001/archopht.1982.01030030137016 · Cited by 1,177
Kerrigan, L. A., Quigley, H. A., Pease, M. E., Kerrigan, D., & Mitchell, R. S. (2000) · PubMed · Cited by 996
Asrani, S., Zeimer, R., Wilensky, J., Gieser, D., Vitale, S., & Lindenmuth, K. (2000) · Journal of Glaucoma · doi:10.1097/00061198-200004000-00002 · Cited by 901
Risk factors for progression of visual field abnormalities in normal-tension glaucoma
Drance, S., Anderson, D. R., & Schulzer, M. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00964-3 · Cited by 790
Nouri-Mahdavi, K., Hoffman, D., Coleman, A. L., Liu, G., Li, G., Gaasterland, D., & Caprioli, J. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.02.017 · Cited by 704
Micro-invasive glaucoma surgery: current perspectives and future directions
Saheb, H., & Ahmed, I. I. K. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834ff1e7 · Cited by 633
The Prevalence of Glaucoma in a Population-Based Study of Hispanic Subjects: Proyecto VER
Quigley, H. A. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.12.1819 · Cited by 593
Ganglion cell losses underlying visual field defects from experimental glaucoma.
Harwerth, R. S., Carter‐Dawson, L. D., Shen, F., Smith, E. L., III, & Crawford, M. L. J. (1999) · PubMed · Cited by 544
Intraocular Pressure Fluctuation
Caprioli, J., & Coleman, A. L. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.10.031 · Cited by 505
Fluctuation of Intraocular Pressure and Glaucoma Progression in the Early Manifest Glaucoma Trial
Bengtsson, B., Leske, M. C., Hyman, L., & Heijl, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.07.060 · Cited by 454 · cited 2×
“Other authors considered that IOP fluctuation is not an independent risk factor for glaucoma onset or progression.(63,64,68) This discrepancy may be due to the use of different hypotensive medications, different populations and study designs, as well as the lack of a standard definition and reproducibility of IOP fluc…”
Natural History of Open-Angle Glaucoma
Heijl, A., Bengtsson, B., Hyman, L., & Leske, M. C. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.042 · Cited by 394 · cited 2×
“Although there is compelling evidence that ‘‘nonIOP-related factors’’ may indeed have a significant role in glaucoma pathogenesis, IOP is the major component associated with fast progression rate.(13) In a recent review on the pathophysiology of glaucoma, Weinreb et al.”
Why Do Some People Go Blind from Glaucoma?
Grant, W. M., & Burke, J. F. (1982) · Ophthalmology · doi:10.1016/s0161-6420(82)34675-8 · Cited by 390
Risk Factors for Visual Field Progression in Treated Glaucoma
De Moraes, C. G. V. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.72 · Cited by 356 · cited 1×
“Establishing a target peak IOP is clinically easier than establishing a target mean IOP in many patients.(54) Despite this advantage and some evidence in the literature that peak IOP may play a greater role on progression than mean IOP, comparative studies investigating whether treatment interventions based on peak or…”
Self-citationMusch, D. C., Gillespie, B. W., Niziol, L. M., Lichter, P. R., & Varma, R. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.047 · Cited by 351
The probability of blindness from open-angle glaucoma
Hattenhauer, M. G., Johnson, D. H., Ing, H. H., Herman, D. C., Hodge, D. O., Yawn, B. P., Butterfield, L. C., & Gray, D. T. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)91133-2 · Cited by 326 · cited 2×
“These figures are very similar to the data presented by Hattenhauer et al.89 who found a 54% risk of unilateral blindness and a 22% risk of bilateral blindness after 20 years among treated glaucoma patients.”
Adherence with Topical Glaucoma Medication Monitored Electronically
Okeke, C. O., Quigley, H. A., Jampel, H. D., Ying, G.-S., Plyler, R. J., Jiang, Y., & Friedman, D. S. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.004 · Cited by 305 · cited 1×
“In a randomized clinical trial testing whether interventions can improve rates of adherence (as determined by an electronic dosing aid device), investigators found no significant difference in IOP between the intervention and observation groups, although adherence increased by 20%.(96) On the other hand, Rossi et al.”
Risk Factors for the Development of Glaucomatous Visual Field Loss in Ocular Hypertension
Quigley, H. A. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090170088028 · Cited by 304
Doctor–Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma
Friedman, D. S., Hahn, S. R., Gelb, L., Tan, J., Shah, S. N., Kim, E. E., Zimmerman, T. J., & Quigley, H. A. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.11.023 · Cited by 297
Barkana, Y. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.6.793 · Cited by 278 · cited 4×
“Limitations to these approaches are that more than 50% of IOP peaks occur outside office hours.(52) In addition to this”
InfluentialPrevalence and predictors of open-angle glaucoma Results from the visual impairment project
Weih, L. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00799-0 · Cited by 252 · cited 2×
“Weih et al.21 also reported that increased time since last visit to an eye care provider was associated with elevated risk of undiagnosed glaucoma.”
Rates of visual field progression in clinical glaucoma care
Heijl, A., Buchholz, P., Norrgren, G., & Bengtsson, B. (2013) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.02492.x · Cited by 224 · cited 1×
“ment of rate of progression in routine care is often recommended for glaucoma management.(72,73)”
Visual Field Defects and Retinal Ganglion Cell Losses in Patients With Glaucoma
Harwerth, R. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.6.853 · Cited by 222
Risk assessment in the management of patients with ocular hypertension
Weinreb, R. N., Friedman, D. S., Fechtner, R. D., Cioffi, G. A., Coleman, A. L., Girkin, C. A., Liebmann, J. M., Singh, K., Wilson, M. R., Wilson, R., et al. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.04.054 · Cited by 204 · cited 1×
“Lucia study(81) and OHTS,(80) the number needed to treat (NNT) to prevent blindness in one patient for 15 years is 83.(33) However, one should be reminded that this NNT is applicable to a 15-year follow-up and that a large proportion of OHT patients are diagnosed at a young age (the mean age at baseline in the OHTS wa…”
Self-citationBlindness in patients with treated open-angle glaucoma
Chen, P. P. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01974-7 · Cited by 200
Lifetime Risk of Blindness in Open-Angle Glaucoma
Peters, D., Bengtsson, B., & Heijl, A. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.027 · Cited by 198 · cited 4×
“In a retrospective chart review by Peters et al.8 in Sweden, at the time of the last visit 42.2% and 16.4% of patients had at least one eye blind or bilateral blindness from glaucoma, respectively.”
InfluentialThe relationship between visual field loss in glaucoma and health-related quality-of-life
van Gestel, A., Webers, C. A. B., Beckers, H. J. M., van Dongen, M. C. J. M., Severens, J. L., Hendrikse, F., & Schouten, J. S. A. G. (2010) · Eye · doi:10.1038/eye.2010.133 · Cited by 197 · cited 2×
“For instance, it has been shown that the impact of dry eyes secondary to glaucoma medications on quality-of-life is similar to a 10 dB loss in the visual field MD.71 For some patients, certain types of medical therapy or surgery are contraindicated despite detected IOP peaks considered hazardous.”
Temba glaucoma study: a population-based cross-sectional survey in urban South Africa
Rotchford, A. P., Kirwan, J. F., Muller, M. A., Johnson, G. J., & Roux, P. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01568-3 · Cited by 189 · cited 3×
“Rotchford AP, Kirwan JF, Muller MA, et al. Temba glaucoma study: a population-based cross-sectional survey in urban South Africa.”
InfluentialPrediction of Functional Loss in Glaucoma From Progressive Optic Disc Damage
(2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.276 · Cited by 188 · cited 1×
“The development of a rim notch or a new disc hemorrhage, for example, may provide the basis for more aggressive treatment even in the absence of statistically significant visual field abnormalities.(45,46) In a recent analysis of rates of visual field change and why glaucoma patients go blind from glaucoma in the Unit…”
Medeiros, F. A., Weinreb, R. N., Zangwill, L. M., Alencar, L. M., Sample, P. A., Vasile, C., & Bowd, C. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.012 · Cited by 172 · cited 2×
“Other authors considered that IOP fluctuation is not an independent risk factor for glaucoma onset or progression.(63,64,68) This discrepancy may be due to the use of different hypotensive medications, different populations and study designs, as well as the lack of a standard definition and reproducibility of IOP fluc…”
Delaying Treatment of Ocular Hypertension: The Ocular Hypertension Treatment Study
(2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.20 · Cited by 172 · cited 2×
“Kass et al.84 proposed that OHT individuals at high risk of developing OAG may benefit from more frequent examinations and early preventive treatment.”
DeLeo´n-Ortega, J. E., Arthur, S. N., McGwin, G., Xie, A., Monheit, B. E., & Girkin, C. A. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1239 · Cited by 170
Burden of Undetected and Untreated Glaucoma in the United States
Shaikh, Y., Yu, F., & Coleman, A. L. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.08.023 · Cited by 166
Do Adherence Rates and Glaucomatous Visual Field Progression Correlate?
Rossi, G. C. M., Pasinetti, G. M., Scudeller, L., Radaelli, R., & Bianchi, P. E. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.6112 · Cited by 165 · cited 2×
“In a randomized clinical trial testing whether interventions can improve rates of adherence (as determined by an electronic dosing aid device), investigators found no significant difference in IOP between the intervention and observation groups, although adherence increased by 20%.96 On the other hand, Rossi et al.97…”
MethodRate of visual field loss and long-term visual outcome in primary open-angle glaucoma
Kwon, Y. H., Kim, C.-S., Zimmerman, M. B., Alward, W. L. M., & Hayreh, S. S. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00912-6 · Cited by 158
Baseline Risk Factors that Predict the Development of Open-Angle Glaucoma in a Population
Jiang, X., Varma, R., Wu, S., Torres, M., Azen, S. P., Francis, B. A., Chopra, V., & Nguyen, B. B.-T. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.05.030 · Cited by 156
Factors Associated with Undiagnosed Open-Angle Glaucoma: The Thessaloniki Eye Study
Topouzis, F., Coleman, A. L., Harris, A., Koskosas, A., Founti, P., Gong, G., Yu, F., Anastasopoulos, E., Pappas, T., & Wilson, M. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.09.013 · Cited by 155
Reus, N. J., Lemij, H. G., Garway‐Heath, D. F., Airaksinen, P. J., Antón, A., Bron, A. M., Faschinger, C. W., Holló, G., Iester, M., Jonas, J. B., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.09.026 · Cited by 152
Quigley, H. A., Tielsch, J. M., Katz, J., & Sommer, A. H. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72062-8 · Cited by 149
Drance, S. M. (1963) · Archives of Ophthalmology · doi:10.1001/archopht.1963.00960050304004 · Cited by 144 · cited 1×
“IOP peaks are potentially an important cause of glaucoma progression and most of the time are not detected during office hours.(52,56) Twenty-four-hour”
Bengtsson, B., & Heijl, A. (2005) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-1103-8 · Cited by 137 · cited 1×
“Other authors considered that IOP fluctuation is not an independent risk factor for glaucoma onset or progression.(63,64,68) This discrepancy may be due to the use of different hypotensive medications, different populations and study designs, as well as the lack of a standard definition and reproducibility of IOP fluc…”
Risk Factors for Visual Field Progression in the Low-pressure Glaucoma Treatment Study
Moraes, C. G. D., Liebmann, J. M., Greenfield, D. S., et al. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.04.015 · Cited by 136
Patterns of Care for Open-angle Glaucoma in Managed Care
Fremont, A. M. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.6.777 · Cited by 120 · cited 2×
“Freemont et al.78 obtained data on working-age patients with OAG enrolled in managed care plans between 1997 and 1999.”
Long-Term Trends in Glaucoma-Related Blindness in Olmsted County, Minnesota
Malihi, M., Filho, E. R. M., Hodge, D. O., & Sit, A. J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.003 · Cited by 113 · cited 2×
“observed reduction in rates of blindness observed recently.(9)”
Kymes, S. M., Kass, M. A., Anderson, D. R., Miller, J. P., & Gordon, M. O. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.01.019 · Cited by 107 · cited 2×
“Also, based on the OHTS data, Kymes et al.(83) suggested that delay of treatment for all people with ocular hypertension until glaucoma-related symptoms are present appears to be unnecessarily conservative.”
Vessani, R. M., Moritz, R. B., Batis, L., Zagui, R. M. B., Bernardoni, S., & Susanna, R. (2009) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31818153da · Cited by 105 · cited 1×
“These technologies perform well against the gold standard of expert judgment.(25,26) Considering that the newest modalities of OCT have an average sensitivity of around 70% to 80% at a fixed specificity of 80%,(27) the”
Self-citationMottet, B., Aptel, F., Romanet, J.-P., Hubanova, R., Pépin, J.-L., & Chiquet, C. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.5297 · Cited by 94
Is There More to Glaucoma Treatment Than Lowering IOP?
Mozaffarieh, M., & Flammer, J. (2007) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2007.08.013 · Cited by 90
Peak Intraocular Pressure and Glaucomatous Progression in Primary Open-Angle Glaucoma
Konstas, A. G. P., Quaranta, L., Mikropoulos, D. G., Nasr, M. B., Russo, A., Jaffee, H. A., Stewart, J. A., & Stewart, W. C. (2011) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0081 · Cited by 86
Franca, J. R., Foureaux, G., Fuscaldi, L. L., Ribeiro, T. G., Rodrigues, L. B., Bravo, R., Castilho, R. O., Yoshida, M. I., Cardoso, V. N., Fernandes, S. O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095461 · Cited by 83 · cited 1×
“In another study, prostaglandin-loaded inserts were administered into the conjunctival sac of rats and resulted in significant IOP lowering with decreased RGC loss compared to controls.(103) There are ongoing clinical trials testing the safety and efficacy of these new drug delivery systems in humans and we expect the…”
Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles
Kim, Y. C., Edelhauser, H. F., & Prausnitz, M. R. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-14651 · Cited by 81 · cited 1×
“In animal models, researchers have been able to safely deliver prostaglandins and alphaagonist agents to the supraciliary space leading to significant IOP lowering and allowing multiple-dose sparing (up to 100-fold).(102) In another study, prostaglandin-loaded inserts were administered into the conjunctival sac of rat…”
Factors Predicting the Rate of Functional Progression in Early and Suspected Glaucoma
Gardiner, S. K., Johnson, C. A., & Demirel, S. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9065 · Cited by 80
Hahn, S. R., Friedman, D. S., Quigley, H. A., Kotak, S. V., Kim, E., Onofrey, M., Eagan, C. A., & Mardekian, J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.11.026 · Cited by 67 · cited 2×
“For instance, Hahn et al.(95) showed that a 3-hour educational program can significantly improve physician’s communication strategies and ability to detect and address nonadherence to glaucoma therapy.”
Bartz‐Schmidt, K. U., Thumann, G., Jonescu-Cuypers, C. P., et al. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(99)00076-4 · Cited by 66
Baseline mean deviation and rates of visual field change in treated glaucoma patients
Forchheimer, I., Moraes, C. G. D., Teng, C. C., Folgar, F. A., Tello, C. A., Ritch, R. H., & Liebmann, J. M. (2011) · Eye · doi:10.1038/eye.2011.33 · Cited by 46 · cited 2×
“Forchheimer et al.(4) investigated the relationship between baseline visual field damage, IOP, and rate of progression and”
Self-citationMoraes, C. G. V. D., Furlanetto, R. L., Reis, A. S. C., Vegini, F., Cavalcanti, N. F., & Susanna, R. (2009) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2009.02003.x · Cited by 39
Self-citationSustained drug delivery in glaucoma
Knight, O. J., & Lawrence, S. D. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000031 · Cited by 32 · cited 2×
“In addition, new drug delivery systems have been described for glaucoma medical therapy and may potentially help decrease the burdens of nonadherence.(101) In animal models, researchers have been able to safely deliver prostaglandins and alphaagonist agents to the supraciliary space leading to significant IOP lowering…”
Visual field testing in glaucoma Medicare beneficiaries before surgery
Coleman, A. L., Yu, F., & Rowe, S. G. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.09.034 · Cited by 24 · cited 2×
“of Medicare beneficiaries in the United States, Coleman et al.(76) found that the use of visual field testing”
InfluentialA Critical Reevaluation of Current Glaucoma Management
Caprioli, J., & Garway‐Heath, D. F. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.032 · Cited by 21
Blumberg, D. M., Vaswani, R. S., Nong, E., Al‐Aswad, L. A., & Cioffi, G. A. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14014 · Cited by 20 · cited 2×
“In a simulation model testing its potential usefulness as a screening tool, Blumberg et al.(28) found that the use of spectral domain OCT as a screening tool could decrease the prevalence of undiagnosed glaucoma from 75% to 38%.”
Self-citationSelective Citation of Evidence Regarding Photoreceptor Loss in Glaucoma
Quigley, H. A. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.9.1390 · Cited by 18
Visual Fields and OCT Role in Diagnosis of Glaucoma
Bae, H. W., Lee, K. H., Lee, N., Hong, S., Seong, G. J., & Kim, C. Y. (2014) · Optometry and Vision Science · doi:10.1097/opx.0000000000000394 · Cited by 17 · cited 3×
“In fact, digital imaging devices improve general ophthalmologists’ ability to diagnose glaucoma,(26) as well as their level of agreement.(29) Bae et al.”
InfluentialAccuracy of Matching Optic Discs with Visual Fields
van der Schoot, J., Reus, N. J., Garway‐Heath, D. F., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.05.026 · Cited by 14
Into the Looking Glass: Factors and Opportunities to Reshape Eye Care in the Next 25 Years
Lee, P. P. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.046 · Cited by 9
Unpredictability of glaucoma progression
Susanna, R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903098867 · Cited by 9 · cited 1×
“Added to that, in many patients progression is not linear and the interpatient variability is large.(13,92)”
Self-citation
Metadata
- Authors
- Susanna, R., De Moraes, C. G., Cioffi, G. A., & Ritch, R.
- Venue
- Translational Vision Science & Technology
- Published
- 2015-03
- Volume
- 4
- Issue
- 2
- Pages
- 1
- ISSN
- 2164-2591 (ISSN-L)
- OpenAlex
- W1970239628
- Cited by
- 198
- References
- 75
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.